Gene therapy Market Key Highlights and Future Opportunities Till 2035

The global gene therapy market is estimated to grow from $2.4 billion in 2024 to $16.5 billion by 2035, representing a CAGR of 19.25% during the forecast period till 2035.

The gene therapy market landscape has transformed significantly since the approval of the world’s first gene therapy, Gendicine®, in the early 2000’s. Ever since then, with the constant R&D efforts of the gene therapy companies and non-industry stakeholder, an increasing number of therapies have entered the gene therapy market. It is worth highlighting that, more than 390 gene therapies have either received regulatory approval or are currently being evaluated in across various phases of clinical trials to assess the safety and effectiveness of these medications in patients diagnosed with different types of inherited disorders. In fact, close to 5% of the gene therapies have already been marketed, of which 30% of the therapies are intended for the treatment of various hematological disorders that are caused due to abnormalities in specific genes of an individual. Additionally, at present, 920 gene therapies are either in discovery stage or being evaluated in preclinical studies, of which 60% of the therapies are being developed to be delivered using adeno-associated virus vectors. Further, during our research, we identified 345 gene therapy developers / gene therapy companies that are engaged in the development of gene therapies.
The majority (58%) of gene therapy developers were established during the period 2011-2020. This period has seen a notable increase in the number of players entering the gene therapy domain, reflecting a stable and enticing industry for the new entrants. In fact, the positive clinical outcomes demonstrated by these therapies in real-world scenarios have attracted several start-ups to enter the domain. As such, it is worth mentioning that since 2020, close to 30 developers have entered the market, indicating the growing interest of stakeholders in this field. Notable examples of such players (in reverse chronological order) include Addimmune (2023), Stemcardia (2023), Celosia Therapeutics (2022), Theriva Biologics (2022), Borea Therapeutics (2021), Gromit Therapeutics (2021) and Ray Therapeutics (2021).
Close to 80% of the marketed and clinical stage gene therapies have received orphan drug designation. This can be attributed to the fact that around 80% of rare diseases worldwide are genetic in nature. Hence, in order to overcome the burden associated with these conditions, regulatory bodies have proactively granted orphan drug designations (granted to drugs developed for the treatment of rare diseases ) to gene therapies that have demonstrated clinical efficacy in addressing the underlying genetic cause of such orphan indications. This is followed by gene therapies that have received fast track designation (48%) and rare pediatric disease designation (31%).
Further, close to 90% of marketed and clinical stage gene therapies are delivered using the in vivo method primarily due to the fact that in vivo gene delivery is typically a simpler process, which involves direct administration of genetic material to the target organ within the body. Moreover, unlike ex vivo gene therapies, in vivo gene delivery is a less-invasive process, as it minimizes the need for procedures such as cell extraction and in vitro genetic modification; thereby maximizing the patient compliance to these gene therapies. Further, over 10% of the gene therapies that are currently being developed are delivered using ex vivo methods. Examples of marketed gene therapies delivered through ex vivo method (arranged in alphabetical order) includes Casgevy™ (CRISPR Therapeutics and Vertex Pharmaceuticals), INVOSSA® (Kolon TissueGene) and Libmeldy™ (Orchard Therapeutics and SR-Tiget).
Majority (60%) of preclinical and discovery stage gene therapies are delivered using adeno-associated virus vectors. This is followed by therapies delivered using non-viral vectors (14%) and lentivirus vectors (7%). Notable examples of gene therapies delivered using non-viral vectors (arranged in alphabetical order, being developed for treatment of genetic disorders) include CS-104 (CorrectSequence Therapeutics), EG-i08 (enGene), GF-1003 (Genflow Biosciences) and RY107 (Reyon Pharmaceutical and MDimune).
Further, a maximum (23%) of the preclinical and discovery stage gene therapies are being developed for the treatment of neurological disorders. It is important to note that neurological disorders are currently the second leading cause of death worldwide. In fact, according to the World Federation of Neurology, in 2023, over 40% of the global population had suffered from some form of neurological conditions and these statistics are likely to double by 2050. As a result, there is an alarming need to develop effective therapies that can target the root cause of these diseases and can address the current unmet needs. In this regard, gene therapies have emerged as a promising therapeutic modality as they are designed to cross the blood-brain barrier and deliver functional genes, potentially treating a range of inherited neurological disorders.
Thank you for reading our report. Kindly get in touch with us to know more about the report or to receive a customized copy of it. Our team will ensure the report is tailored according to your needs.
To view more details on this report, click on the link
https://www.rootsanalysis.com/....reports/gene-therapi

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
We specialise in analysing areas which have lacked quality research so far or require more focused understanding within the broader industry. All our reports are structured in a way to enable the reader develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we also provide bespoke research / consulting services dedicated to serve our clients in the best possible way.
The research efforts are driven by a global team. The leadership team brings a wealth of experience within the sector. Their collective experience in pharmaceutical / affiliated domains allows us to tackle various areas of research in a structured way. We also regularly leverage our global network of experts who hold senior leadership positions in reputed firms and organisations worldwide.
Contact:
Roots Analysis
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Gaurav.chaudhary@rootsanalysis.com
Website: https://www.rootsanalysis.com/

Flow Cytometry Market Key Highlights and Future Opportunities Till 2035

The latest report entitled ‘Flow Cytometry Market’ by Roots Analysis provides an accurate estimation of the market size, regional landscape description, and revenue forecast over the projected timeframe.

The global flow cytometry market size is valued at USD 5.1 billion in 2024 and is poised to reach USD 10.75 billion in 2032, representing a CAGR of 8.25% during the forecast period. The report turns the spotlight on the major challenges faced by the key players in the global market and the growth strategies currently adopted by them. The report is a granular assessment of this particular business sphere and entirely covers the dynamic competitive landscape of the market. The document offers key insights into the market positions of these players alongside their gross earnings. Furthermore, it elaborates on each of the market segments, with detailed scrutiny of the development scope and competitive scenario of the regional fragments of the market.

The latest study is inclusive of an in-depth analysis of the economic status of the Flow Cytometry Market and examines the most important regions constituting the global market. It further details on the most lucrative and growth-oriented regions, top market rivals, diversified product types, and a large number of end-use industries.


Key factors affecting the growth of the Flow Cytometry Market:
Geographical Overview:
• The latest report broadly categorizes the Flow Cytometry Market into several geographical terrains, including North America, Europe, Asia, Latin America, MENA and Rest of the World.
• The study is inclusive of essential information relevant to each region in this broad industry segment, along with the key drivers of the regional market growth.
• The report further estimates the revenue accumulated by these regions over the forecast period.

Competitive Hierarchy:
• The latest research report studies the major market players, their regional presence, industry share, and production facilities.
• The report offers significant data pertaining to these market competitors’ company profiles, product types, and application outlook.
• Moreover, the pricing models and gross margins of these industry majors have also been mentioned in the report.

Key players
Sysmex Corporation, Agilent Technologies, Inc., BD, Bio-Rad Laboratories, Inc., Beckman Coulter, Inc., Sony Biotechnology Inc., Apogee Flow Systems, Cytek Biosciences, BIOMÉRIEUX, Merck KGaA, Miltenyi Biotec, Takara Bio Inc., Thermo Fisher Scientific, Q2 Solutions, CellKraft Biotech Pvt. Ltd., Sartorius AG, NeoGenomics Laboratories, Cell Signaling Technology, Inc., CytoBuoy, ORFLO Technologies, IKEDA SCIENTIFIC Co., Ltd., BioLegend, Beckman Coulter

Additional parameters of the Flow Cytometry Market report:
• The latest research study endows the reader with a comprehensive analysis of the product types of the Flow Cytometry Market, categorizing the relevant information into the Distribution by Type of Product (Reagents and Consumables, Flow Cytometry Instruments, Accessories, Services, and Software), Type of Technology (Cell-Based Flow Cytometry and Bead-Based Flow Cytometry), Application Area (Research Applications, Clinical Applications, and Industrial Applications), Type of End User (Pharmaceuticals & Biotechnology Companies, Academic & Research Institutes, Hospitals, Clinical Testing Laboratories, Blood Bank, and Others), Type of Distribution Channel (Retail Sales and Direct Tenders) and Key Geographical Regions (North America, Europe and Asia Pacific, Latin America, Middle East and North Africa). The study focuses on the wide-ranging application landscape of the market, segmenting it into the market share, estimated growth rate, and the forecast product demand for each application type.

Additional Insights:
• The market concentration rate and processing rate of raw materials have also been conscripted in the report.
• The report contains an assessment of the current price trends, as well as the factors influencing the global market size.
• It throws light on the significant marketing strategies implemented by the eminent players in the industry.
• Vital data and information concerning the producers, distributors, and downstream buyers involved in the global market, as well as the cost structure analysis and market mechanism, form the important elements of this report.

Research objectives:
• The Flow Cytometry Market report studies the worldwide market consumption rate in terms of value and volume.
• It identifies the various sub-segments of the market structure.
• It proffers information regarding the leading global manufacturers in this industry, describing their market value & share, sales volume, competitive analysis, SWOT analysis, and development strategies adopted during the forecast timeline.
• The report describes the key industry players, with respect to their individual growth trends, future prospects, and contribution to the global market, and explains the factors related to their market growth potential, drivers, opportunities, threats, and industry-specific challenges.
• Furthermore, the report underpins the strategic developments occurring in the Flow Cytometry Market, such as expansions, mergers & acquisitions, agreements, as well as new product launches.

To view more details on this report, click on the link
https://www.rootsanalysis.com/....reports/flow-cytomet

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

We specialise in analysing areas which have lacked quality research so far or require more focused understanding within the broader industry. All our reports are structured in a way to enable the reader develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we also provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

The research efforts are driven by a global team. The leadership team brings a wealth of experience within the sector. Their collective experience in pharmaceutical / affiliated domains allows us to tackle various areas of research in a structured way. We also regularly leverage our global network of experts who hold senior leadership positions in reputed firms and organisations worldwide.

Contact:
Roots Analysis
+1 (415) 800 3415
Sales@rootsanalysis.com

Probiotics Market Trends, Opportunities, Key Players, Growth Factors, Revenue Analysis, 2024-2035

The global probiotics market size is estimated to be $70.9 billion in 2024 and is projected to reach $165.1 billion by 2035. The market is anticipated to grow at a CAGR of 8.0%, during the forecast period till 2035.

To view more details on this report, click on the link
https://www.rootsanalysis.com/....reports/probiotics-m

RNA Therapeutics Market Size, Share, Growth Factors, Competitive Landscape, with Regional Forecast to 2035

Owing to their clinical potential to specifically target and treat various disease indications, the next generation RNA therapeutics and vaccines have gained significant traction and are anticipated to revolutionize the healthcare and medical sector.

The global RNA therapeutics and vaccines market size is estimated to grow from USD 1.2 million in 2023 to USD 948 million by 2035, representing a CAGR of 68% during the forecast period 2023-2035.
Over the years, RNA-based therapeutics and vaccines have been studied extensively for their crucial role in gene function and protein expression regulation. Owing to their vast potential in the treatment of a myriad of disease indications, targeting previously deemed undruggable targets, and high therapeutic efficiency, these molecules have transitioned into a compelling treatment alternative for a range of disorders. However, a major challenge in the implementation of these therapies lies in the highly unstable structure of the RNA molecule. The loose prime terminals of RNA molecules allow quick degradation of these molecules by restriction exonucleases. In recent years, the advent of advanced technologies and platforms has escalated the interest of industry stakeholders towards enhanced and modified RNA-based therapies, that are believed to be highly stable and have an extended impact at relatively low doses.
The types of next generation RNA therapeutics and RNA vaccines include circular RNA (circRNA), endless RNA (eRNA), self activating RNA (sacRNA), self amplifying RNA (saRNA), self amplifying mRNA (samRNA), replicating RNA (repRNA) and transfer RNA (tRNA). The success of these next generation RNA therapeutics and RNA vaccines can be attributed to their structural stability, expression specificity, targeted delivery, non-immunogenic nature, high efficiency and ability to target a wide range of therapeutic modalities, including influenza, COVID-19 infection, breast cancer and interstitial lung disease, among others.
Next generation RNA therapeutics and RNA vaccines offer great promise in the healthcare sector, as a result of which, various drug and technology developers are shifting their focus towards the design, development, manufacturing and delivery of these innovative modalities.
Given the ongoing pace of innovation in this field, encouraging clinical trial results, accelerated approvals, and the continuous efforts of both industry and non-industry players, the next generation RNA vaccines and RNA therapeutics market is likely to witness significant growth during the forecast period.
Over 35 next generation RNA technologies are being developed / offered by companies for the research, discovery, design, development, manufacturing and delivery of novel rna therapies and vaccines.
Currently, over 35 next generation RNA technologies are being developed / offered by industry players. It is worth mentioning that most of the technologies are being deployed for next generation RNA based therapeutics. Examples of technologies used in the development of both self-amplifying RNA therapeutics and vaccines include ChaESAR Technology and VaxEquity’s Next-generation RNA Platform.
The number and geographical distribution of clinical trials are important indicators of both the therapeutic viability and future potential of innovative pharmacological interventions. Over the years, several pharmaceutical / biopharmaceutical companies have conducted extensive clinical studies for only those drug / therapy classes that are likely to translate into commercial success. Moreover, the geographical distribution directly indicates the various markets that are open to receiving / adopting the intervention under investigation. As more product candidates get approved by the regulatory authorities across the globe, the number of clinical trials across different global regions is anticipated to increase.
There was a steady increase in the number of clinical trials registered for the evaluation of next generation RNA therapeutics and vaccines, during the period 2019-2023. This increase can be attributed to the incessant efforts of several industry / non-industry players that are actively developing and testing different types of novel RNA-based approaches for the treatment of a wide range of disorders. It is also worth highlighting that, over the years, most of the trials (33%) were registered in 2022.
Thank you for reading our report. Kindly get in touch with us to know more about the report or to receive a customized copy of it. Our team will ensure the report is tailored according to your needs.
To view more details on this report, click on the link
https://www.rootsanalysis.com/....reports/rna-therapeu

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
We specialise in analysing areas which have lacked quality research so far or require more focused understanding within the broader industry. All our reports are structured in a way to enable the reader develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we also provide bespoke research / consulting services dedicated to serve our clients in the best possible way.
The research efforts are driven by a global team. The leadership team brings a wealth of experience within the sector. Their collective experience in pharmaceutical / affiliated domains allows us to tackle various areas of research in a structured way. We also regularly leverage our global network of experts who hold senior leadership positions in reputed firms and organisations worldwide.
Contact:
Roots Analysis
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Gaurav.chaudhary@rootsanalysis.com
Website: https://www.rootsanalysis.com/

Liquid Biopsy Market Size, Share, Emerging Factors, Trends, Segmentation and Forecast to 2035

The liquid biopsy market size is estimated to grow from USD 6.09 billion in 2024 to USD 29.8 billion by 2035, growing at a CAGR of 15.53% from 2024 to 2035.

Roots analysis research has recently released expansive research titled liquid biopsy market guarantees you will remain better informed than your competition.
Liquid biopsy market report gives explanation about the different segments of the market analysis which is demanded by today’s businesses. Key players are taking actions such as developments, product launches, acquisitions, mergers, joint ventures and competitive analysis in the industry. All the market aspects are estimated and analysed by a team of innovative, enthusiastic and motivated researchers and analysts so that nothing lefts uncovered in the report. Global Liquid Biopsy Market research report, it becomes easy to figure out brand awareness and insight about the brand and product among potential customers.
Key market segmentation:
Liquid biopsy market: distribution by type of product and / or device offered (botox, dermal fillers, chemical peels, body contouring, gluteal implants, hair removal, breast implants and other products and / or devices), type of procedure (non-invasive, minimally invasive and invasive), end user (hospitals, clinics / med spas and dermatology / cosmetology centers, and other end users), gender (male and female), distribution channel (direct distribution and indirect distribution)
Major key player liquid biopsy market
ArcherDX, CellMax Life, ClearNote Health, DiaCarta, Personal Genome Diagnostics, Singlera Genomics, Sysmex Inostics and Helio Genomics.
Objective of liquid biopsy market:
Every firm in the liquid biopsy market has objectives but this market research report focus on the crucial objectives, so you can analysis about competition, future market, new products, and informative data that can raise your sales volume exponentially.
• Size of the liquid biopsy market and growth rate factors.
• Important changes in the future liquid biopsy industry.
• Top worldwide competitors of the market.
• Scope and product outlook of liquid biopsy market.
• Developing regions with potential growth in the future.
• Tough challenges and risk faced in market.
• Global liquid biopsy top manufacturers profile and sales statistics.
Key takeaways from the liquid biopsy market report:
• Detailed considerate of liquid biopsy market-particular drivers, trends, constraints, restraints, opportunities and major micro markets.
• Comprehensive valuation of all prospects and threat in the
• In depth study of industry strategies for growth of the cardiovascular genetic testing market-leading players.
• Liquid biopsy market latest innovations and major procedures.
• Favorable dip inside vigorous high-tech and market latest trends remarkable the market.
• Conclusive study about the growth conspiracy of market for forthcoming years.
Liquid biopsy market country level analysis
The countries covered in the liquid biopsy market report are u.s., canada and mexico in north america, brazil, argentina and rest of south america as part of south america, germany, italy, u.k., france, spain, netherlands, belgium, switzerland, turkey, russia, rest of europe in europe, japan, china, india, south korea, australia, singapore, malaysia, thailand, indonesia, philippines, rest of asia-pacific (apac) in asia-pacific (apac), south africa, saudi arabia, u.a.e, israel, egypt, rest of middle east and africa (mea) as a part of middle east and africa (mea).
Frequently asked questions
1. What is the future market value for liquid biopsy market?
2. What is the growth rate of the liquid biopsy industry?
3. What are the major companies operating in the liquid biopsy market?
4. Which countries data is covered in the liquid biopsy industry?
5. What are the main data pointers covered in liquid biopsy market report?
To know more about this premium research report, visit @ https://www.rootsanalysis.com/....reports/liquid-biops

About roots analysis
Roots analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including fortune 500 companies, start-ups, academia, venture catalysts, and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serving our clients in the best possible way.
The research efforts are driven by a global team. The leadership team brings a wealth of experience within the sector. Their collective experience in pharmaceutical / affiliated domains allows us to tackle various areas of research in a structured way. We also regularly leverage our global network of experts who hold senior leadership positions in reputed firms and organizations worldwide.
All our analysts are trained to produce high-quality research work. They are continuously mentored by senior experts to present an original, unbiased and informed perspective on pressing issues in the industry. On any particular subject, we bring together the best available resources to ensure highest quality in all our reports.
Contact details
Roots analysis
Gaurav chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
gaurav.chaudhary@rootsanalysis.com
Website: https://www.rootsanalysis.com/